Epstein-Barr virus (EBV)-associated lymphoproliferative disease (LPD) is a life-threatening complication following hematopoietic stem cell transplantation (HSCT). Therefore, early diagnosis of EBV reactivation and pre-emptive therapy may be clinically useful. We report three patients who presented with an extremely high EBV load in peripheral blood mononuclear cells and plasma without evidence of EBV disease. Following pre-emptive therapy with a single dose of rituximab, a concordant decrease of EBV-genome copies and B lymphocytes was observed. In all three patients, no EBV-associated LPD occurred. We conclude that pre-emptive therapy with rituximab appears to be effective for prevention of EBV-associated LPD after HSCT.
proliferative disease; pre-emptive therapy; hematopoietic stem cell transplantation Epstein-Barr virus (EBV)-associated lymphoproliferative disease (LPD) is a life-threatening complication following hematopoietic stem cell transplantation (HSCT). The use of unrelated or mismatched related donors, T-cell depletion, the use of antithymocyte globulin (ATG) or anti-CD3 monoclonal antibody for prophylaxis or treatment of graftversus-host-disease (GVHD), and the occurrence of GVHD are risk factors for the development of EBV-associated LPD. 1 Despite new treatment modalities such as donor lymphocyte infusion, infusion of EBV-specific cytotoxic T lymphocytes, and the anti-CD20 monoclonal antibody rituximab, the outcome of established EBV-associated LPD is not optimal. 2 Therefore, early diagnosis of EBV reactivation is crucial for successful therapy. Recently, we have demonstrated that quantitative EBV-specific polymerase chain reaction (PCR) in peripheral blood mononuclear cells (PBMCs) and in plasma is a powerful tool for identifying patients at risk for EBV-associated LPD. 3 Our patient data strongly suggest that an increase of EBV load (410 4 EBV-genome copies/10 5 PBMCs) predicts EBVassociated LPD. This finding prompted us to start preemptive therapy in patients with a high copy number (410 4 EBV-genome copies/10 5 PBMCs) for prevention of EBVassociated LPD. Here, we demonstrate in three patients that rituximab can be used successfully for preventing EBV-associated LPD. All three patients received ATG as part of the conditioning regimen. In all cases, T-cell depletion was performed by positive selection of CD34 + progenitor cells. No patient was given cyclosporin A (CsA) or methotrexate for GVHD prophylaxis.
Case reports

Patient 1
A 14-year-old girl with myelodysplastic syndrome received an allogeneic HSCT from an HLA-identical family donor. At 3 weeks after transplantation, she developed severe acute GVHD and was treated with methylprednisolone and CsA. On day 56 after HSCT, she was found to have an extremely high EBV load (80 000 EBV-genome copies/10 5 PBMCs). At that time, she had no clinical or radiological evidence of EBV disease. PCR detecting rearranged immunoglobulin heavy chain (IGH) genes using DNA from PBMCs revealed monoclonality. 4 We found identical DNA sequences after PCR analysis on days 52, 56, and 60 after HSCT, respectively. We administered a single dose of rituximab (375 mg/m 2 ) on day 60 after HSCT. The monoclonal band disappeared after PCR for rearranged IGH genes on day 84 after HSCT and was absent in all subsequent follow-up samples. Owing to GVHD, the patient required immunosuppressive therapy for 8 months after transplantation. Importantly, she did not develop EBV-associated LPD after pre-emptive therapy with rituximab. She remains disease free 9 months after HSCT.
Patient 2
A 2-year-old boy with juvenile myelomonocytic leukemia underwent allogeneic HSCT from an unrelated donor. On day 47 after HSCT, he presented with an extremely high EBV load (600 000 EBV-genome copies/10 5 PBMCs) without any clinical or radiological evidence of EBV disease. He was given a single dose of rituximab (375 mg/m 2 ) on day 49 after HSCT and did not develop EBV-associated LPD. Unfortunately, he suffered a relapse 5 months after HSCT. Despite donor lymphocyte transfusions and development of severe GVHD, he died of leukemia 7 months after HSCT.
Patient 3
A 9-year-old girl with severe systemic juvenile chronic arthritis received an autologous HSCT. On day 42 after HSCT, she had evidence of an extremely high EBV load (80 000 EBV-genome copies/10 5 PBMCs) without any clinical or radiological evidence of EBV-associated LPD. We administered a single dose of rituximab (375 mg/m 2 ) on day 43 after HSCT. She did not develop EBV-associated lymphoma. Prednisolone was tapered 2 months after transplantation. The patient remains clinically well 8 months after HSCT.
Discussion
All three patients presented with extremely high EBV loads (X80 000 EBV-genome copies/10 5 PBMCs). In our patients, the increase of EBV-genome copies occurred earlier in PBMCs than in plasma. Therefore, PBMCs are more useful than plasma for early diagnosis of EBV reactivation. In all three patients, the number of EBV-genome copies in PBMCs corresponded well with the number of B lymphocytes (Figure 1 ). This finding suggests that the increase of EBV-genome copies in PBMCs correlates well with the increase in EBV-infected B lymphocytes as recently reported. 5 The scales for B lymphocytes/ml are different across the three panels of Figure 1 and might reflect a different number of EBV-genome copies per infected B lymphocytes in each patient. In all three patients, administration of rituximab resulted in a dramatic decrease in EBV-genome copies in PBMCs, rapid clearance of EBVgenome copies from plasma, and effective depletion of B lymphocytes (Figure 1) . In patient 1, EBV load in PBMCs as well as B lymphocytes increased again from day 84 until day 98 after HSCT. Reduction of immunosuppressive therapy after day 98 resulted in a further decrease in both parameters in this patient (Figure 1) .
Rituximab, a chimeric murine/human anti-CD20 monoclonal antibody, depletes both normal and malignant CD20 + pre-B and mature B lymphocytes from the circulation by complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and induction of apoptosis. The rationale for its use in EBV-associated LPD rests on the frequent expression of the CD20 antigen. 6 Patients with established EBV-associated LPDs have been treated with rituximab with variable efficacy. 2, 5, 7 Patients with a large tumor burden of EBV-associated LPD have had a particularly bad response to antibody treatment and a poor survival. 8 Therefore, recognition of EBV reactivation at an early stage before development of EBVassociated LPD is crucial. We have recently demonstrated that both patients with a high copy number (410 4 EBVgenome copies/10 5 PBMCs) developed EBV-associated LPD, whereas this was not observed in any of the three patients who remained below that threshold. 3 Therefore, we decided to start pre-emptive therapy in patients with a high copy number (410 4 EBV-genome copies/10 5 PBMCs) for prevention of EBV-associated LPD. The present cases of successful pre-emptive therapy with rituximab for prevention of EBV-associated LPD confirms the recent report by van Esser et al. 9 Administration of rituximab was well tolerated and the patients did not experience any side effects. None of our patients developed opportunistic infections during the observation period. At most recent follow-up, we observed a decreased CD19 + cell number in patients 1 and 2 and decreased levels of immunoglobulins in patient 1 without evidence of infectious complications. 10 Immune reconstitution of CD3 + , CD4 + , and CD8 + T cells was not affected by rituximab (Table 1 ). PCR detecting rearranged IGH genes using DNA from PBMCs revealed already monoclonality in patient 1. To our knowledge, this is the first report that pre-emptive therapy with rituximab can lead to a disappearance of monoclonality in a patient at high risk for EBV-associated LPD. In conclusion, preemptive therapy with rituximab resulted in a dramatic decrease of EBV-genome copies in PBMCs and plasma and effective depletion of B lymphocytes in patients at high risk for EBV-associated LPD. Administration of rituximab was well tolerated and appeared to be effective for prevention of EBV-associated LPD. Table 1 Immunophenotypic analysis and levels of immunoglobulins in three patients after administration of rituximab Immunoglobulins at most recent follow-up (g/l)
